Marie‐Christine Kyrtsonis

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 327 citations

Medicine, Hematology, Oncology +14

Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide

Meletios Α. Dimopoulos, Athanasios K. Anagnostopoulos, Marie‐Christine Kyrtsonis et al. · Journal of Clinical Oncology · 2007 · 277 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +15

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi et al. · The Lancet Oncology · 2016 · 236 citations

Life Sciences, Immunology, Pharmacotherapy +12

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Meletios Α. Dimopoulos, Ramón García‐Sánz, Maria Gavriatopoulou et al. · Blood · 2013 · 207 citations · Full text

Medicine, Hematology, Pharmacotherapy +16